PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
ANNÉE
2021
AUTEURS
Ducreux Ml, Parzy A, Ben Abdelghani M, Martin-Babau J, Tougeron D, Botsen D, Taieb J, Pannier D, Khemissa F, Viaud J, Villing AL, Bouché O, Peytier A, Alexandre H, Garic F, Tanguy M-L, Bachet J-B
CONGRÈS/REVUE
ESMO
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES